MedTrace Logo

Phase III Study of Gemcitabine Compared With UFT in Patients With Completely Resected Pathological Stage IB-IIIa Non Small Cell Lung Cancer

NCT00139971 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2006-01-06

No results posted yet for this study

Summary

To estimate the efficacy of Gemcitabine monotherapy compared to UFT as the post operative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Conditions

Interventions

DRUG

gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6

DRUG

UFT 250mg/m2, daily for 1 year

Sponsors & Collaborators

  • West Japan Thoracic Oncology Group

    lead OTHER

Principal Investigators

  • Hirohito Tada, MD · West Japan Thoracic Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-12-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00139971 on ClinicalTrials.gov